Related Experiment Video
Updated: Jun 21, 2026
10:28
Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs
Published on: April 14, 2015
33.2K
Plasma microRNA Profiling in Type 2 Diabetes Mellitus: A Pilot Study
Ziravard N Tonyan1, Yury A Barbitoff1, Yulia A Nasykhova1
1Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 199034 St. Petersburg, Russia.
International Journal of Molecular Sciences
|December 23, 2023
Summary
Researchers identified specific microRNAs (miRNAs) in plasma that differ between type 2 diabetes (T2D) patients and healthy individuals. These circulating miRNAs may serve as biomarkers for T2D and its complications.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Diseases
Background:
- Type 2 diabetes (T2D) is a chronic metabolic disorder defined by insulin resistance and impaired beta-cell function.
- T2D leads to significant microvascular and macrovascular complications, impacting patient health globally.
- Circulating microRNAs (miRNAs) are emerging as potential biomarkers for various diseases, including metabolic disorders.
Purpose of the Study:
- To investigate circulating miRNA expression profiles in plasma from type 2 diabetes (T2D) patients and healthy controls.
- To identify specific miRNAs that are differentially expressed in T2D and correlate with obesity.
- To perform functional analysis of identified miRNAs and their target genes.
Main Methods:
- Plasma samples from 44 T2D patients and 22 healthy individuals were analyzed using next-generation sequencing for miRNA expression profiling.
- Statistical analysis was employed to detect differentially expressed miRNAs between groups.
- Bioinformatic tools were used for identification and functional enrichment analysis of putative target genes for key miRNAs.
Main Results:
- A total of 229 differentially expressed miRNAs were detected between T2D patients and healthy controls.
- Specific miRNAs, including increased miR-5588-5p, miR-125b-2-3p, miR-1284, and decreased miR-496, were identified in T2D patients.
- Differential expression of miR-144-3p and miR-99a-5p was observed in obese individuals within the T2D cohort.
- Functional analysis indicated that target genes of identified miRNAs are involved in chromatin modification and apoptosis.
Conclusions:
- Circulating miRNA profiles in plasma can distinguish T2D patients from healthy individuals.
- Specific miRNAs like miR-5588-5p, miR-125b-2-3p, miR-1284, and miR-496 show altered expression in T2D.
- Obesity-associated miRNAs (miR-144-3p, miR-99a-5p) were identified, suggesting a link between metabolic status and miRNA dysregulation.
- The identified miRNAs and their target pathways offer potential for novel diagnostic biomarkers and therapeutic targets for T2D.
Keywords:
miR-125b-2-3pmiR-1284miR-144-3pmiR-496miR-5588-5pmiR-99a-5pmiRNAobesitytype 2 diabetes mellitusMore Related Videos
10:34Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
6.5K
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.7K
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...